Anti-TPOR/ MPL/ C-MPL monoclonal antibody
Anti-TPOR/ MPL/ C-MPL antibody for FACS & in-vivo assay
Go to MPL/MPL products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T16156-Ab-1/ GM-Tg-hg-T16156-Ab-2 | Anti-Human MPL monoclonal antibody | Human |
GM-Tg-rg-T16156-Ab-1/ GM-Tg-rg-T16156-Ab-2 | Anti-Rat MPL monoclonal antibody | Rat |
GM-Tg-mg-T16156-Ab-1/ GM-Tg-mg-T16156-Ab-2 | Anti-Mouse MPL monoclonal antibody | Mouse |
GM-Tg-cynog-T16156-Ab-1/ GM-Tg-cynog-T16156-Ab-2 | Anti-Cynomolgus/ Rhesus macaque MPL monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T16156-Ab-1/ GM-Tg-felg-T16156-Ab-2 | Anti-Feline MPL monoclonal antibody | Feline |
GM-Tg-cang-T16156-Ab-1/ GM-Tg-cang-T16156-Ab-2 | Anti-Canine MPL monoclonal antibody | Canine |
GM-Tg-bovg-T16156-Ab-1/ GM-Tg-bovg-T16156-Ab-2 | Anti-Bovine MPL monoclonal antibody | Bovine |
GM-Tg-equg-T16156-Ab-1/ GM-Tg-equg-T16156-Ab-2 | Anti-Equine MPL monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T16156-Ab-1/ GM-Tg-hg-T16156-Ab-2; GM-Tg-rg-T16156-Ab-1/ GM-Tg-rg-T16156-Ab-2; GM-Tg-mg-T16156-Ab-1/ GM-Tg-mg-T16156-Ab-2; GM-Tg-cynog-T16156-Ab-1/ GM-Tg-cynog-T16156-Ab-2; GM-Tg-felg-T16156-Ab-1/ GM-Tg-felg-T16156-Ab-2; GM-Tg-cang-T16156-Ab-1/ GM-Tg-cang-T16156-Ab-2; GM-Tg-bovg-T16156-Ab-1/ GM-Tg-bovg-T16156-Ab-2; GM-Tg-equg-T16156-Ab-1/ GM-Tg-equg-T16156-Ab-2 |
Products Name | Anti-MPL monoclonal antibody |
Format | mab |
Target Name | MPL |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-MPL benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Biosimilar | GMP-Bios-INN-977 | Pre-Made Romiplostim Biosimilar, Fusion Protein targeting MPL fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting C-MPL/CD110/MPLV/THCYT2/THPOR/TPOR |
Target Antigen | Products Developing | Multi-species TPOR/ MPL/ C-MPL VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMLP005099 | human MPL Lentivirus plasmid |
ORF Viral Vector | vGMLP005099 | human MPL Lentivirus particle |
Target information
Target ID | GM-T16156 |
Target Name | MPL |
Gene ID | 4352,17480,366455,610801,101097002,528492,100066544 |
Gene Symbol and Synonyms | C-MPL,CD110,hlb219,MPL,MPLV,THCYT2,THPOR,TPO-R,TPOR |
Uniprot Accession | P40238 |
Uniprot Entry Name | TPOR_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, INN Index |
Disease | Cancer |
Gene Ensembl | ENSG00000117400 |
Target Classification | Cytokine receptor, Tumor-associated antigen (TAA) |
The target: MPL, gene name: MPL, also named as C-MPL, CD110V, THCYT2, TPOR, MPL. In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.